Trial intelligence / Profile preview

Gilteritinib versus midostaurin with intensive chemotherapy in newly diagnosed FLT3-mutated AML or MDS-EB2

NL-OMON54682Phase 3Active, not recruiting

Sponsor

HOVON

Start

Dec 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1